## Fluoroquinolone Adverse Effects: Comprehensive Review ### Correct Answer Analysis **Key Point:** Option B is the EXCEPT answer because the statement that peripheral neuropathy is "usually irreversible" is factually incorrect. Fluoroquinolone-associated peripheral neuropathy is generally **reversible** upon drug discontinuation, though recovery may be slow and incomplete in some cases. The FDA's 2013 and 2016 warnings acknowledge that symptoms may persist, but the characterization of "usually irreversible" overstates the clinical reality. ### Why Option B is the EXCEPT (Incorrect Statement) **Peripheral Neuropathy — Partially Correct but Overstated:** - Fluoroquinolones can cause peripheral neuropathy (paresthesias, burning, weakness) - Mechanism: Mitochondrial dysfunction and impaired axonal transport - Timeline: Can occur during therapy or shortly after cessation - **Reversibility: Generally reversible after discontinuation**, though recovery may be slow; a minority of patients have prolonged symptoms - The FDA label states symptoms "may be irreversible" — NOT "usually irreversible" - Harrison's Principles and KD Tripathi both note that neuropathy is typically reversible with drug withdrawal **Mnemonic:** **FQAD** = **F**luoroquinolone-**A**ssociated **D**isability — a term used for the rare severe, persistent cases, NOT the typical presentation ### Confirmed Adverse Effects of Fluoroquinolones (Options A, C, D are TRUE) #### 1. Cardiac Toxicity — QT Prolongation (Option A — TRUE) **High-Yield:** Fluoroquinolones block cardiac hERG potassium channels → QT prolongation → risk of torsades de pointes. | Agent | QT Risk | | --- | --- | | **Moxifloxacin** | High | | **Gemifloxacin** | High | | **Levofloxacin** | Moderate | | **Ciprofloxacin** | Low | **Clinical Pearl:** Risk increases with hypokalemia, hypomagnesemia, female sex, and concurrent QT-prolonging drugs. #### 2. Glucose Dysregulation (Option C — TRUE) **High-Yield:** Fluoroquinolones cause both hypoglycemia AND hyperglycemia through modulation of pancreatic β-cell KATP channels (same target as sulfonylureas). - **Hypoglycemia:** Stimulation of insulin secretion (especially gatifloxacin, levofloxacin) - **Hyperglycemia:** Inhibition of insulin secretion - Gatifloxacin was withdrawn from clinical use largely due to severe dysglycemia - This IS a recognized, FDA-labeled adverse effect of the fluoroquinolone class - Reference: KD Tripathi Essentials of Medical Pharmacology, 8th ed.; Harrison 21e Ch 297 #### 3. Photosensitivity (Option D — TRUE) **High-Yield:** Older fluoroquinolones (nalidixic acid, norfloxacin, lomefloxacin) cause photosensitivity more frequently than newer agents. - Mechanism: Photochemical activation → phototoxic dermatitis - Presentation: Erythema, blistering on sun-exposed areas - Newer agents (levofloxacin, moxifloxacin) have lower risk ### Other Important Adverse Effects - **Tendinopathy/tendon rupture:** Achilles tendon most common; risk with corticosteroids, elderly - **CNS toxicity:** Seizures, hallucinations (especially in elderly, renal failure) - **Aortic aneurysm/dissection:** Rare but serious - **C. difficile infection:** Dysbiosis-related [cite:KD Tripathi Essentials of Medical Pharmacology 8e; Harrison 21e Ch 297; FDA Drug Safety Communication 2016]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.